Order Details Sample Clauses

Order Details. A. Initial implementation service fee (one-time fee) $10,000 The Initial Implementation Fee includes installation of the Aeon™ Software on your local server, staff training and basic customization assistance to help configure the system.
AutoNDA by SimpleDocs
Order Details. Idearc must make requests for Listing Information by NPA/NXX combination or other geographic location identifier agreeable to the TOCs. Idearc may request selected Listing Information, to the extent reasonably available to the TOCs (e.g., business only, residential only, government only, new installations or any combination thereof). The TOCs will use reasonable efforts to accommodate requests that the Listing Information provided exclude certain listings, such as data or fax line listings, when feasible.
Order Details. 1.10 The Service Period is to be replaced with: 36 months
Order Details. 3.1. Details of order and payment are specified in the order confirmation to which the user has agreed by orders. After payment, the Argus license will be active within 3 working days.
Order Details. 2.1. You may place an order for a licence to use the Product (“Licence”) through the Land App website or directly through the Product (collectively defined as the “Website”), for a prescribed period (“Licence Period”). The order will detail the applicable fees, the duration of the Licence and you will need to submit your payment details and make payment in accordance with clause 3. The Licence may be for full access to the Product or for certain features only, as specified in the applicable order.

Related to Order Details

  • Notice Details Party A: Swiss Re Financial Products Corporation Address: 00 Xxxx 00/xx/ Xxxxxx 00/xx/ Xxxxx Xxx Xxxx XX 00000 XXX Facsimile No.: +0 000 000 0000 Attention: Head of Operations Party B: Permanent Financing (No. 6) PLC Address: Xxxxxxxxx Xxxxx Xxxxxxxxx Xxxx Xxxxxx XX0X 0XX Facsimile Number: 020 7566 0975 Attention: The Secretary With a copy to: (i) the Security Trustee:

  • Payment Details You will make all Payments due under this Master Agreement by 12:00 P.M., Connecticut time, on the day they are due. You will make all Payments in US Dollars (US$) in immediately available funds. We do not have to make or give "presentment, demand, protest or notice" to get paid. You waive "presentment, demand, protest and notice."

  • Account Details (a) Account for payments to Counterparty: To be provided. Account for delivery of Shares to Counterparty: To be provided.

  • Contact details (a) Except as provided below, the contact details of each Party for all communications in connection with the Finance Documents are those notified by that Party for this purpose to the Facility Agent on or before the date it becomes a Party.

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order.

  • Originating Switched Access Detail Usage Data A category 1101XX record as defined in the EMI Telcordia Practice BR-010-200- 010.

  • Data Universal Number System (DUNS) number Requirement Grantee will provide their valid DUNS number contemporaneous with execution of this Agreement.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Details A detail is the temporary assignment of an employee, with no change in pay, to a different position or to a different set of duties for a specific period, with the employee returning to his or her regular or similar duties at the end of the detail. The employee continues to be the incumbent of the position from which they are detailed.

  • Invoice Detail Contractor’s invoice must be on Contractor’s stationary with Contractor’s name, address, and remittance address if different. Contractor’s invoice must have a date, an invoice number, a purchase order number, a description of the goods or services provided, and an amount due.

Time is Money Join Law Insider Premium to draft better contracts faster.